Cyclosporine 2% eye drops preparation;Préparation d'un collyre de ciclosporine à 2%

Journal Francais d'Ophtalmologie

Volumn 27, Issue 6 I, 2004, Pages 567-576

  Chast, F ^a   Lemare, F ^a   Legeais, J M ^a   Batista, R ^a   Bardin, C ^a   Renard, G ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CASTOR OIL; CYCLOSPORIN; CYCLOSPORIN A; EYE DROPS; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CORNEA DISEASE; CORNEA TRANSPLANTATION; DILUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PHARMACY; HUMAN; IMMUNOPATHOLOGY; ROOM TEMPERATURE; SIDE EFFECT; TOXICITY; UVEA DISEASE; VALIDATION PROCESS;

EID: 3242883166     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(04)96181-5     Document Type: Article

References (79)

1. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf, 2002;25:33-55.
2. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology, 1999;106:723-8.
3. Kulkarni P. Review: uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther, 2001;17:181-7.
4. Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol, 1986;31:159-69.
5. Tamesis RR, Rodriguez A, Christen WG, Akova YA, Messmer E, Foster CS. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology, 1996;103:768-75.
6. Borel JF, Feurer C, Gübler HU, Stähelin H. Biological action of cyclosporine A: a new antilymphocytic agent? Agents and Actions, 1976;6:468-75.
7. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 1993;45:953-1040.
8. Beveridge T, Calne RY. Cyclosporine (Sandimmun) in cadaveric renal transplantation. Ten-year follow-up of a multicenter trial. European Multicentre Trial Group. Transplantation, 1995;59:1568-70.
9. Wakefield D, McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol, 1991;7:221-6.
10. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med, 1989;321:1353-9.
11. Young AL, Rao SK, Cheng LL, Wong AK, Leung AT, Lam DS. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye, 2002;16:304-8.
12. Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye, 2001;15:39-41.
13. Avunduk AM, Avunduk MC, Erdol H, Kapicioglu Z, Akyol N. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica, 2001;215:290-3.
14. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci, 2001;42:90-5.
15. Mariette X. Current and potential treatments for primary Sjogren's syndrome. Joint Bone Spine, 2002;69:363-6.
16. Tabbara KF, Vera-Cristo CL. Sjogren syndrome. Curr Opin Ophthalmol, 2000;11:449-54.
17. Gunduz K, Ozdemir O. Topical cyclosporin treatment of kerato-conjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh), 1994;72:438-42.
18. McCoombes JA, Hirst LW, Green WR. Use of topical cyclosporin for conjunctival manifestations of actinic prurigo. Am J Ophthalmol, 2000;130:830-1.
19. Chen J, Xie H, Wang Z, Yang B, Liu Z, Chen L et al. Mooren's ulcer in China: a study of clinical characteristics and treatment. Br J Ophthalmol, 2000;84:1244-9.
20. Hoang-Xuan T, Prisant O, Hannouche D, Robin H, Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology, 1997;104:1300-5.
21. Hingorani M, Calder VL, Buckley RJ, Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci, 1999;40:392-9.
22. Reinhard T, Sundmacher R. Topical cyclosporin A in Thygeson's superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol, 1999;237:109-12.
23. Shimura M, Yasuda K, Fuse N, Nakazawa M, Tamai M. Effective treatment with topical cyclosporin A of a patient with Cogan syndrome. Ophthalmologica, 2000;214:429-32.
24. Kiang E, Tesavibul N, Yee R, Kellaway J, Przepiorka D. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant, 1998;22:147-51.
25. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology, 1994;101:822-31.
26. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol, 1985;1:369-82.
27. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology, 1996;103:365-73.
28. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol, 1996;234(Suppl 1):S115-21.
29. Ilari L, Daya SM. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. Ophthalmology, 2002;109:1278-84.
30. Inoue K, Amano S, Kimura C, Sato T, Fujita N, Kagaya F et al. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol, 2000;44:302-5.
31. Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ. Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens, 2003;292:103-7.
32. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy. Ophthalmology, 1994;101:128-33.
33. Robert PY, Delbosc B, Preux PM, Monnot PH, Drouet M, Peyronnet P, Adenis JP. Traitement par la ciclosporine A, à doses faibles, dans les kératoplasties transfixiantes à haut risque. Étude bicentrique de 90 cas. J Fr Ophtalmol, 1997;20:507-14.
34. Filipec M, Phan TM, Zhao TZ, Rice BA, Merchant A, Foster CS. Topical cyclosporine A and corneal wound healing. Cornea, 1992;11:546-52.
35. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol, 1996;234(Suppl 1):S115-21.
36. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol, 2002;86:988-92.
37. Hoang-Xuan T, Prisant O, Hannouche D, Robin H. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology, 1997;104:1300-5.
38. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology, 1996;103:365-73.
39. Benezra D, Maftzir G. Ocular penetration of cyclosporine A in the rat eye. Arch Ophthalmol, 1990;108:584-7.
40. Anonyme. Ophthalmic cyclosporine (Restasis®) for dry eye disease, Allergan. Med Lett Drugs Ther, 2003;45:42-3.
41. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology, 2000;107:631-9.
42. Goichot-Bonnat L, De Beauregard C, Saragoussi JJ, Pouliquen Y. Utilisation d'un collyre de cyclosporine A dans la prévention du rejet de greffe de cornée chez l'homme. J Fr Ophtalmol, 1987;10:207-11.
43. Perry HD, Donnenfeld ED, Acheampong A, Kanellopoulos AJ, Sforza PD, D'Aversa G, Wallerstein A et al. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J, 1998;24:159-65.
44. Zhao JC, Jin XY. Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol, 1995;119:189-94.
45. Bonnes Pratiques de Pharmacie Hospitalière, 2001 (juin) - Projet de circulaire ministérielle.
46. Husek A. High performance liquid chromatographic analysis of cyclosporin A and its oral solutions. J Chrom B, 1997;759:217-24.
47. Fiscella RG, Le H, Lam TT, Labib S. Stability of cyclosporine 1% in artificial tears. J Ocul Pharmacol Ther, 1996;12:1-4.
48. Behrens-Baumann W, Theuring S, Brewitt H. The effect of topical cyclosporin A on the rabbit cornea. A clinical and electron microscopic study. Graefes Arch Clin Exp Ophthalmol, 1986;224:520-4.
49. Knagenhjelm SK, Froyland K, Ringvold A, Bjerkas E, Kjonniksen I. Toxicological evaluation of cyclosporine eyedrops. Acta Ophthalmol Scand, 1999;77:200-3.
50. Secchi AG, Tognon MS, Leonardi A. Topical cyclosporine A in the treatment of vernal and other immunologycally mediated kerato-conjunctivitis. In: Ocular immunology today. Ed: Usui M, Ohno S et Aoki K. Pub Excerpta Medica, Amsterdam; 1990.
51. Menezo JL, Martinez-Costa R, Navea A, Roig V, Cisneros A. Excimer laser photorefractive keratectomy for high myopia. J Cataract Refract Surg, 1995;21:393-7.
52. Knagenhjelm SK, Froyland K, Ringvold A, Bjerkas E, Kjonniksen I. Toxicological evaluation of cyclosporine eyedrops. Acta Ophthalmologica Scandinavica, 1999;77:200-3.
53. Xie L, Shi W, Wang Z, Bei J, Wang S. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea, 2001;20:748-52.
54. Reidy JJ, Gebhardt BM, Kaufman HE. The collagen shield. A new vehicle for delivery of cyclosporin A to the eye. Cornea, 1990;9:196-9.
55. Gebhardt BM, Varnell ED, Kaufman HE. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J Ocul Pharmacol Ther, 1995;11:509-17.
56. Milani JK, Pleyer U, Dukes A, Chou HJ, Lutz S, Ruckert D et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology, 1993;100:890-6.
57. Alghadyan AA, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposome-bound cyclosporine: clearance after intravitreal injection. Int Ophthalmol, 1988;12:109-12.
58. Vallelado Al, Lopez MI, Calonge M, Sanchez A, Alonso MJ. Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats. Curr Eye Res, 2002;24:39-45.
59. de Rojas Silva MV, Rodriguez-Ares MT, Sanchez-Salorio M, Lamas Diaz MJ, Cuevas Alvarez J, Vila Jato JL et al. Efficacy of sub-conjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit. Graefes Arch Clin Exp Ophthalmol, 1999;237:840-7.
60. Juberias JR, Calonge M, Gomez S, Lopez MI, Calvo P, Herreras JM et al. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr Eye Res, 1998;17:39-46.
61. Le Bourlais CA, Chevanne F, Turlin B, Acar L, Zia H, Sado PA et al. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study. J Microencapsul, 1997;14:457-67.
62. Robert PY, Leconte V, Olive C, Ratsimbazafy V, Javerliat M, Adenis JP. Collyre de ciclosporine: préparation, toxicité, pharmacocinétique et indications en 2000. J Fr Ophtalmol, 2001;24:527-35.
63. Solch S, Nadler PI, Silverman MH. Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers. J Ocul Pharmacol, 1991;7:301-12.
64. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol, 2002;89:298-303.
65. Benitez del Castillo JM, del Aguila C, Duran S, Hernandez J, Garcia Sanchez J. Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability. Cornea, 1994;13:136-40.
66. Newton C, Gebhardt BM, Kaufman HE. Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest Ophthalmol Vis Sci, 1988;29:208-15.
67. van der Bijl P, van Eyk AD, Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea, 2001;20:505-8.
68. Mendicute J, Aranzasti C, Eder F, Ostolaza JI, Salaberria M. Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis. Eye, 1997;11(Pt 1):75-8.
69. Minguez E, Tiestos MT, Cristobal JA, Castillo J, Dapena MP, Palomar A. Absorption intraoculaire d'un collyre de cyclsoporine A. J Fr Ophtalmol, 1992;15:263-7.
70. Kanpolat A, Batioglu F, Yilmaz M, Akbas F. Penetration of cyclosporin A into the rabbit cornea and aqueous humor after topical drop and collagen shield administration. CLAO J, 1994;20:119-22.
71. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology, 1991;98:1679-84.
72. Theng J, Zhou L, Tan D, La KW. Distribution of cyclosporin A in the cornea after topical or oral administration. J Ocul Pharmacol Ther, 2002;18:83-8.
73. Benitez del Castillo JM, Castillo A, Toledano N, Duran S, del Aguila C, Otero M et al. Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein. Doc Ophthalmol, 1995;91:49-55.
74. Kurlansky PA, Sadeghi AM, Michler RE, Coppey LJ, Re LP, Thomas WG et al. Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. J Heart Transplant, 1986;5:312-6.
75. e édition), 1997:1876-7.
76. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology, 1989;96:1144-50.
77. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology, 2000;107:967-74.
78. Small DS, Acheampong A, Reis B, Stern K, Stewart W, Berdy G et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther, 2002;18:411-8.
79. Kachi S, Hirano K, Takesue Y, Miura M. Unusual corneal deposit after the topical use of cyclosporine as eyedrops. Am J Ophthalmol, 2000;130:667-9.